Key facts
- Philia Labs’s last known valuation is $4.4M (Dec 2024).
- It has raised $2.1M; the latest was Later Stage VC ($630K) in Dec 2024.
- Notable investors include Artesian, Medtech Actuator.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Philia Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Philia Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Philia Labs
Developer of a depression management platform designed to measure acute and chronic stress in the body. The company's platform offers stress measurement from biometrics with aggregated reporting and clinically validated algorithms to quantify stress, enabling clinicians to monitor depression patients at risk of relapse.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2018
- Employees
- 8
- Website
- philialabs.com.au/
- Ownership
- Privately Held (backing)
Philia Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Philia Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Philia Labs in its N-PORT filings yet. We sweep new filings monthly.